PE20140647A1 - Metodo para tratamiento de cancer de pulmon de celulas no pequenas - Google Patents

Metodo para tratamiento de cancer de pulmon de celulas no pequenas

Info

Publication number
PE20140647A1
PE20140647A1 PE2013002522A PE2013002522A PE20140647A1 PE 20140647 A1 PE20140647 A1 PE 20140647A1 PE 2013002522 A PE2013002522 A PE 2013002522A PE 2013002522 A PE2013002522 A PE 2013002522A PE 20140647 A1 PE20140647 A1 PE 20140647A1
Authority
PE
Peru
Prior art keywords
lung cancer
nucleotides
small cell
cell lung
cancer treatment
Prior art date
Application number
PE2013002522A
Other languages
English (en)
Inventor
Chen Duksin
Shoshi Tessler
Martin E Gleave
Original Assignee
Teva Pharma
Univ British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47177396&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20140647(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma, Univ British Columbia filed Critical Teva Pharma
Publication of PE20140647A1 publication Critical patent/PE20140647A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) UN TAXANO TAL COMO PACLITAXEL; B) UN AGENTE QUIMIOTERAPEUTICO CON BASE EN PLATINO TAL COMO CARBOPLATINO; Y C) UN OLIGONUCLEOTIDO ANTI-CLUSTERINA EN UNA CANTIDAD DE 640MG QUE COMPRENDE LA SECUENCIA CAGCAGCAGAGTCTTCATCAT (SEQ ID N�: 1) Y QUE TIENE i) UNA COLUMNA DE FOSFOROTIOATO, ii) PORCIONES DE AZUCAR DE LOS NUCLEOTIDOS 1-4 Y 18-21 QUE LLEVAN MODIFICACIONES DE 2'-O-METOXIETILO, iii) 2' DESOXINUCLEOTIDOS EN LOS NUCLEOTIDOS 5-17, Y iv) 5-METILCITOSINAS EN LOS NUCLEOTIDOS 1, 4 Y 19. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE CANCER DE PULMON DE CELULAS NO PEQUENAS DE ETAPA IV, METASTASICO O AVANZADO
PE2013002522A 2011-05-19 2012-05-18 Metodo para tratamiento de cancer de pulmon de celulas no pequenas PE20140647A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161487918P 2011-05-19 2011-05-19
US201161493346P 2011-06-03 2011-06-03

Publications (1)

Publication Number Publication Date
PE20140647A1 true PE20140647A1 (es) 2014-06-05

Family

ID=47177396

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013002522A PE20140647A1 (es) 2011-05-19 2012-05-18 Metodo para tratamiento de cancer de pulmon de celulas no pequenas

Country Status (16)

Country Link
US (1) US20130017272A1 (es)
EP (1) EP2709673A4 (es)
JP (1) JP2014520081A (es)
KR (1) KR20140034838A (es)
CN (1) CN103958681A (es)
AR (1) AR086514A1 (es)
AU (1) AU2012257487A1 (es)
CA (1) CA2836676A1 (es)
CL (1) CL2013003324A1 (es)
EA (1) EA201391725A1 (es)
IL (1) IL227720A0 (es)
MX (1) MX2013013384A (es)
PE (1) PE20140647A1 (es)
SG (1) SG194931A1 (es)
WO (1) WO2012156817A2 (es)
ZA (1) ZA201309254B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE385237T1 (de) 1999-02-26 2008-02-15 Univ British Columbia Antisense-therapie für trpm-2
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
KR20140038388A (ko) 2011-03-15 2014-03-28 더 유니버시티 오브 브리티쉬 콜롬비아 전립선암의 치료를 위한 항-클러스테린 올리고뉴클레오타이드와 hsp90 저해제의 병용
UY34812A (es) * 2012-05-18 2013-12-31 Teva Pharma Método para el tratamiento del cáncer de pulmón de células no pequeñas
US20140275215A1 (en) * 2013-03-14 2014-09-18 Teva Pharmaceutical Industries, Ltd. Anti-clusterin monotherapy for cancer treatment
WO2014159774A1 (en) * 2013-03-14 2014-10-02 Teva Pharmaceutical Industries Ltd. Custirsen treatment with reduced toxicity
US20160324439A1 (en) * 2015-05-06 2016-11-10 Taiwan Textile Research Institute Stereoscopic conductive fabric and module for detecting electrical signals from body skin applying the same
WO2016191751A1 (en) * 2015-05-28 2016-12-01 Bristol-Myers Squibb Company Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
JP6792294B2 (ja) * 2015-05-29 2020-11-25 ダイナバックス テクノロジーズ コーポレイション 肺のがんを処置するためのポリヌクレオチドのＴｏｌｌ様受容体９アゴニストの肺内投与
KR20190115505A (ko) 2018-03-15 2019-10-14 특허법인 해담 기업 맞춤형 후속 개발 아이템 발굴 방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7569551B2 (en) * 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
ES2307942T3 (es) * 2002-01-17 2008-12-01 The University Of British Columbia Oligonucleotidos antisentido biespecificos que inhiben igfbp-2 e igfbp-5 y metodos de uso.
US8710020B2 (en) * 2004-04-02 2014-04-29 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
WO2006029023A2 (en) * 2004-09-02 2006-03-16 Isis Pharmaceuticals, Inc. Polymeric beads for oligonucleotide synthesis

Also Published As

Publication number Publication date
WO2012156817A3 (en) 2013-02-21
CN103958681A (zh) 2014-07-30
IL227720A0 (en) 2013-09-30
MX2013013384A (es) 2014-06-11
EP2709673A2 (en) 2014-03-26
ZA201309254B (en) 2015-05-27
EP2709673A4 (en) 2014-12-17
CL2013003324A1 (es) 2014-08-01
WO2012156817A9 (en) 2013-01-03
CA2836676A1 (en) 2012-11-22
AR086514A1 (es) 2013-12-18
SG194931A1 (en) 2013-12-30
WO2012156817A2 (en) 2012-11-22
KR20140034838A (ko) 2014-03-20
US20130017272A1 (en) 2013-01-17
EA201391725A1 (ru) 2014-05-30
JP2014520081A (ja) 2014-08-21
AU2012257487A1 (en) 2014-01-16

Similar Documents

Publication Publication Date Title
PE20140647A1 (es) Metodo para tratamiento de cancer de pulmon de celulas no pequenas
CL2012000021A1 (es) Composiciones de oligonucleótidos; oligonucleótidos; composiciones farmacéuticas que contienen las composiciones; y uso de las composiciones de oligonucleótidos en el tratamiento del cáncer, tal como cáncer pancreático
MX2022014502A (es) Composiciones y metodos para escision quimica y desproteccion de oligonucleotidos unidos a superficie.
BR112018013808A2 (pt) dinucleotídeos cíclicos para o tratamento de condições associadas à atividade de sting, tal como câncer
NZ778462A (en) Coumarin compounds and their uses as fluorescent labels
HK1129045A1 (en) Chemically modified oligonucleotide primers for nucleic acid amplification
CL2008002073A1 (es) Compuestos derivados de lactama tetraciclicos, inhibidores de mk-2; procedimiento de praparacion; composicion farmaceutica; y su uso en el tratamiento de artritis, sinovitis aguda, tendinitis, soriasis, miocarditis, caquexia, asma, cancer, entre otras.
EA201171335A1 (ru) Вектор гена
CL2013003105A1 (es) Compuestos de microarn que comprende secuencias de nucleósidos modificados, inhibidores de mir-21; usos de los compuestos para modular la actividad de mir -21 y para preparar un medicamento para tratar fibrosis, heridas o cancer
WO2010041913A3 (ko) Grs 단백질 또는 이의 단편의 신규한 용도
MX2020013384A (es) Compuestos de comarina sustituidos con amina exocíclica y sus usos como etiquetas fluorescentes.
PE20120115A1 (es) Composiciones y metodos para inhibir la expresion de genes del factor vii
BR112012012008A2 (pt) célula, ácidos nucleicos, enzimas e seu uso bem como processo para a produção de soforolipídios.
BR112015000710A8 (pt) Oligonucleotídeos para fazer uma alteração na sequência de um presente alvo de molécula de rna em uma célula viva
EA201492148A1 (ru) Способ лечения немелкоклеточного рака легких
EA201791182A1 (ru) Новые производные 2'- и/или 5'-аминокислотных эфиров фосфороамидатов 3'-дезоксиаденозина в качестве противораковых соединений
BR112015005172A2 (pt) módulo de biorreator eletroquímico e métodos de seu uso
MX2013005875A (es) Inhibidores de microarn que comprenden nucleotidos bloqueados.
BR112013002738A2 (pt) métodos e compostos para o diagnóstico e o tratamento do câncer
BR112022006476A2 (pt) Oligonucleotídeos com análogos de nucleosídeos
BR112015022308A8 (pt) oligonucleotídeos antissenso para o tratamento de células-tronco cancerosas
AR078921A1 (es) Composiciones y metodos para inhibir la expresion de genes de la superfamilia de quinesinas, kif10
BR112012019866A2 (pt) composto, composição farmacêutica, método de tratamento das infecções virais, e, processo para preparar um composto
BRPI0517387A8 (pt) Oligonucleotídeos anti-senso para o tratamento de alergia e proliferação de células neoplásicas
AR069224A1 (es) Complejo de acido nucleico y ciclodextrina altamente ramificada y composicion para el suministro de acido nucleico

Legal Events

Date Code Title Description
FD Application declared void or lapsed